SteadyMed Adds Significant Commercial Expertise to Its Board of Directors With the Appointment of Elizabeth A. Cermak SAN RAMON, Calif., June 18, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...

SteadyMed to Present at the JMP Securities Life Sciences Conference SAN RAMON, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...

SteadyMed Submits Application for Orphan Drug Designation for Trevyent(R) For Pulmonary Arterial Hypertension SAN RAMON, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY) a specialty pharmaceutical company, today announced that it has submitted an application to the U.S. Food and Drug...

SteadyMed Granted Additional U.S. Patent With Patent Term Extension SAN RAMON, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY) a specialty pharmaceutical company, today announced the issuance of a new patent from the United States Patent and...

SteadyMed Appoints David W. Nassif as Its Full Time Executive Vice President and Chief Financial Officer SAN RAMON, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company, today announced the appointment of David W. Nassif as its full time Executive...